We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+2.69%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$414M
AUM Growth
-$24.8M
Cap. Flow
+$88.7M
Cap. Flow %
21.41%
Top 10 Hldgs %
52.02%
Holding
86
New
35
Increased
13
Reduced
20
Closed
18

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$19.1M
2
SNY icon
Sanofi
SNY
+$18.3M
3
LH icon
Labcorp
LH
+$13.4M
4
COR icon
Cencora
COR
+$11.5M
5
CRL icon
Charles River Laboratories
CRL
+$7.22M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$19.5M
2
BMY icon
Bristol-Myers Squibb
BMY
+$12.5M
3
ICLR icon
Icon
ICLR
+$12.2M
4
JNJ icon
Johnson & Johnson
JNJ
+$9.06M
5
ACH
Accendra Health
ACH
+$7.11M

Sector Composition

Rank Sector Weight
1 Healthcare 72.05%
2 Industrials 1.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRVI icon
76
Maravai LifeSciences
MRVI
$922M
– –
-29,838
Closed -$1.46M
RGLS
77
DELISTED
Regulus Therapeutics
RGLS
– –
-354,721
Closed -$2.45M
XENE icon
78
Xenon Pharmaceuticals
XENE
$6.24B
– –
-62,743
Closed -$959K
KLRS
79
Kalaris Therapeutics
KLRS
$99.7M
– –
-1,932
Closed -$1.11M
PDCO
80
DELISTED
Patterson Companies, Inc.
PDCO
– –
-26,799
Closed -$808K
BLU
81
DELISTED
BELLUS Health Inc.
BLU
– –
-389,833
Closed -$2.39M
CYAD
82
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
– –
-145,380
Closed -$596K
IVC
83
DELISTED
Invacare Corporation
IVC
– –
-1,146,068
Closed -$323K
TRIL
84
CALL
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-206,800
Closed -$36.3M
1 2 3
4

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Endurant Capital Management held 86 positions worth $414M, down 5.7% from $439M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Endurant Capital Management deployed $88.7M of net new capital in Q4 2021, opening 35 new positions and adding to 13 existing holdings. Its largest new stake was AstraZeneca: 162,364 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 60% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Johnson & Johnson, an estimated $9.06M trimmed.

  • Endurant Capital Management's largest Q4 2021 buy was AstraZeneca: 162,364 shares worth $18.9M.
  • Endurant Capital Management added most to Sanofi in Q4 2021, an estimated $18.3M increase.
  • Endurant Capital Management's biggest Q4 2021 reduction was Johnson & Johnson, cutting an estimated $9.06M.
  • Endurant Capital Management fully exited AbbVie in Q4 2021, selling an estimated $19.5M.
  • Endurant Capital Management's ten largest holdings make up 52% of its $414M portfolio in Q4 2021.
  • Endurant Capital Management opened 35 new positions and closed 18 in Q4 2021.
  • Endurant Capital Management's portfolio value fell 5.7% quarter-over-quarter to $414M.

Based on Endurant Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.